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Abstract

Nanoparticles, although considered a topic of modern medicine, actually have an interesting
history. Currently, advances in nanomedicine hold great promise as drug carrier systems for
sustained release and targeted delivery of diverse therapeutic agents. Nanoparticles can be defined
as complex drug carrier systems which incorporate and protect a certain drug or particle.
Nanoparticles can be administered via different routes, such as intravenous injection, oral
administration, or pulmonary inhalation. Even though the use of nano-carriers via pulmonary
inhalation is heavily debated, this system represents an attractive alternative to the intravenous or
oral routes, due to the unique anatomical and physiological features of the lungs and the minimal
interactions between the targeted site and other organs. Some of the widely used nano-carriers for
the treatment of chronic pulmonary diseases, via pulmonary route, are as follows: polymeric
nanoparticles, liposomal nano-carriers, solid lipid nanoparticles, and submicron emulsions. Nanocarrier systems provide the advantage of sustained-drug release in the lung tissue resulting in
reduced dosing frequency and improved patient compliance. Further studies focusing on
understanding the mechanisms of action of nanoparticles and improving their chemical structure
are required in order to better understand the potential long-term risk of excipient toxicity and
nanoscale carriers.
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Highlights

✓ In chronic lung diseases, nano-carrier systems provide the advantage of sustained drug
release in lung tissue, resulting in reduced dosing frequency and improved patient
compliance.
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✓ Further studies are required in order to better understand the potential long-term risk of
excipient toxicity and nanoscale carriers.
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Introduction
Nanoparticles, although considered a topic of modern
medicine, actually have an interesting history, as their use
dates back to the 9th century Mesopotamia, where they
were used by manufacturers to create a glittering effect on
the surface of pots. They were created by mixing copper,
silver salts, and oxides, together with vinegar, ochre, and
clay, on the surface of previously-glazed pottery. The
object was then placed in an oven and heated to about
600°C.
The first scientific characterization—no longer in
use—in terms of optical properties of nanometric metals
was formulated by Michael Faraday in his classic paper
“Experimental relations of gold (and other metals) to
light”. The paper, both philosophical and scientific,
described a series of experiments of ultramicroscopic
particles of gold in various liquids, in order to establish
whether their optical properties suffer any changes under
such conditions. Faraday formulates the following
statement: “It is well known that when thin leaves of gold
or silver are mounted upon glass and heated to a
temperature that is well below a red heat (~500 °C), a
remarkable change of properties takes place, whereby the
continuity of the metallic film is destroyed. The result is
that white light is now freely transmitted, reflection is
correspondingly diminished, while the electrical resistivity
is enormously increased (1).
In the late 1960s, Prof. Speiser at the Swiss Federal
Institute of Technology in Zurich developed the first
nanoparticles for drug delivery purposes and for vaccines
against tetanus, diphtheria, and other infections (2).
Currently, further advances in nanomedicine hold a great
promise as drug carrier systems for sustained release and
targeted delivery of diverse therapeutic agents (3).
Nanoparticles can be defined as complex drug carrier
systems, which incorporate and protect a certain drug or
particle (4). Nanoparticles can be administered via
different routes, such as intravenous injection, oral
administration, and pulmonary inhalation. Due to their
submicron sizes, intravenously injected nanoparticles can
easily escape the altered blood vessels, such as those found
in tumors, trauma, or inflammatory sites. In these
pathological lesions, as a result of the defective lymphatic
drainage of these tissues, nanoparticles are retained for
longer periods of time (5). Using nanoparticles as oral drug
carriers can protect the active ingredient in the
gastrointestinal tract against proteolytic enzymes, prolong
the action of the drug in the mucous membrane, and
facilitate the drug transport across the intestinal mucosa,
making this a comfortable drug administration method (4).

Even though the use of nano-carriers via pulmonary
inhalation is heavily debated, this system represents an
attractive alternative to the intravenous or oral routes, due
to the unique anatomical and physiological features of the
lungs and the minimal interactions between the targeted
site and other organs (6).

Discussions
The purpose of this research was to summarize the
current literature regarding the advantages and
disadvantages of the use of nanoparticles in the treatment
of respiratory diseases, such as COPD (Chronic
Obstructive Pulmonary Disease), asthma, lung cancer, or
tuberculosis, the most clinical common chronic lung
diseases. An important aspect to discuss is the last decade’s
progress in the development of nano-carrier systems for the
treatment of chronic pulmonary diseases, in terms of
chemistry, bio-distribution, and toxicity. Over 2,500
papers have been published in the past 10 years regarding
nanoparticles, proving the exhaustive efforts that are
focused on developing this new and promising class of
drugs.
An electronic search in PubMed database and Web of
Science was conducted on publications from February
2009 to February 2019. Only studies published in English
were included. In the databases, the search used the
following keywords “nanoparticles” and “respiratory
disease”. The studies were then searched manually from
the reference list through the databases.
The inclusion criteria were: articles written in English,
full-text articles, studies published in the last 10 years, and
all studies performed in vitro, ex vivo, and in vivo.
Exclusion criteria were literature reviews and studies about
nanoparticles that were correlated with diseases other than
chronic respiratory ones. The outcome measure in this
research was the roles of nanoparticle therapy in chronic
pulmonary diseases.
The major advantages of nanoparticle-mediated drug
delivery to the lung are attributed to the unique
pharmacokinetic and pharmacodynamic properties of the
system and the anatomical and physiological particularities
of the respiratory tract. The human respiratory tract has a
large surface area (greater than 100m2), a thin lung-blood
barrier (approx. 0.1 microns), and a high perfusion rate,
thus providing quick and efficient access to the circulatory
system. Nanoparticles are particulate drug carrier systems
which incorporate a certain drug in order to coat, protect,
and increase its function. Drugs used for the treatment of
pulmonary diseases can be administered via oral,
intravenous, or inhalation routes, the last being the most
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attractive option in terms of low side effects and high biodistribution (7).
Drug delivery to the lung requires particles sized
between 1 and 5 microns administered by means of
nebulization, pressurized metered dose inhalers (MDI),
and dry powder inhalers (DPI) (8). Metered dose inhalers
are breath-actuated auto-halers that release the medication
during inhalation, and there are no-breath-actuated
pressurized inhalers in which medication is released by
pushing the canister down into the holder, such as
budesonide/formoterol or fluticasone propionate or
salmeterol xinafoate (9). The active ingredients in MDI
inhalers are dissolved or suspended in a propellant, and
they are delivered via a compact pressurized aerosol
dispenser.
Dry powder inhalers are a group of inhalers that contain
medication in very fine dry powder form. They are
classified into single dose devices, multiple unit dose
devices, and multi-dose devices. These tend to be more
popular with patients because they are all breath-actuated.
Examples of DPI are formoterol fumarate, mometasone
furoate, salmeterol xinafoate, tiotropium bromide, and so
on (10). The rate required to deliver the medication in MDI
inhalers is about 30L/min, while the rate required for DPIs
is higher (ranging between 30-120L/min) (10).
In the case of DPI, the force of inhalation plays a key
role in the deposition of particles. If the force is
insufficient, the particles will not reach the lungs and will
be deposited in the upper airways (mouth, pharynx, larynx
and trachea). For MDI, despite the high speed of the
generated aerosol, the key role is represented by good
synchronization between the inhalation and the
administration of the drug (9).
For a better penetration through the respiratory mucosa
and an enhanced local effect, the idea of administering
classic therapies, such as bronchodilators, antiinflammatories, chemotherapy, or tuberculostatic agents
through nano-particulate formulations has emerged.
The pharmacodynamics of nanoparticle carrier systems
is as follows: once the nano-carrier formulation reaches the
lung, it goes through mucociliary clearance (MCC) and
clearance. The mucociliary clearance transports the
particles and the mucus produced by the lung epithelium
towards the upper airways to be swallowed. Meanwhile,
some of the particulate material is recognized by the
antigen presenting cells, such as alveolar macrophages and
dendritic cells. The alveolar macrophages depredate and
possibly deposit the drug, therefore the material ending up
here is mostly lost (11). Dendritic cells present the drug to
the nearby lymph nodes where they are recognized by the
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lymphocytes, leading to an immune reaction, thus
providing a new alternative for the administration of
antigens and vaccines. Only a small part of the inhaled
nano-particulate formulations is able to avoid the
mucociliary clearance, therefore various muco-penetrative
molecules are being researched. Two major ideas have
emerged: some studies show that small particles with a
hydrophilic surface layer and a slight negative charge have
a higher chance of penetrating the mucus (12). Other
studies show that the addition of polyethene-glycolic acid
to the surface of the nanoparticle (known as the process of
PEGylation) provides an increased diffusion in human
mucus and prevents the formation of drug aggregates (13).
The major benefits of nanoparticles administered to the
lung are as follows: uniform distribution of the drug (14,
15), enhanced solubility and dissolution rate (16, 17),
sustained release (18), delivery of various macromolecules
(19, 20), and internalization by cells (21, 22).
Some of the widely used nano-carriers for the treatment
of chronic pulmonary diseases, via the pulmonary route,
are as follows: polymeric nanoparticles, liposomal nanocarriers, solid lipid nanoparticles, and submicron
emulsions (23).
➢ Polymeric nanoparticles are composed of
biodegradable or biocompatible materials such as
polylactic acid, alginic acid, gelatin, and chitosan, which
results in prolonged drug release (24). They are currently
used in several chronic pulmonary diseases such as asthma,
tuberculosis (TB) (25, 26), and pulmonary hypertension
(27).
➢ Liposomal nano-carriers are uni-multi-lamellar
spherical nanoparticles made of lipid bilayer membranes,
including cholesterol and phosphatidylcholine, delivered
in a liquid and dry powder form (28-31). The most valuable
function of this nano-system is the increase in cellular
uptake of the drug due to the presence of cells penetrating
peptides. They have proven themselves useful in treating
respiratory distress syndrome (32).
➢ Solid lipid nano-carriers are composed of solid lipids,
surfactants, and water. They have less or almost no
cytotoxic effect compared to the polymer-based carriers, as
shown in different studies: in vitro, ex vivo, and in vivo
(33-35). Their main use is represented by lung cancer
treatment and TB (tuberculosis) vaccine delivery. Solid
lipid nano-carriers represent a multifunctional strategy in
which a single molecule allows detection, diagnosis,
imaging, cell destruction, and delivery of drugs, decreasing
drug-related side effects (36, 37). More tolerable to the
lungs and major advantages of solid lipid nanoparticles are
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the controlled release of drugs with rapid in vivo
degradation (38-40).
➢ Submicron emulsions are promising carriers for DNA
vaccines (e.g. Mycobacterium tuberculosis) to the lung
compared to the commercially available liposomes. The
emulsion systems are able to transfect pulmonary epithelial
cells, which directly activate dendritic cells, resulting in the
stimulation of antigen-specific T-cells (41).
The type of formulation, composition, shape, and size
are all important determinants in the pulmonary delivery of
nanoparticles (42, 43).
The delivery of the drug requires drug formulations
capable of inhalation and delivery of the active component
to the lower respiratory tract (44). In vivo, the particle sizedependent regional deposition in the lung is variable,
explaining why all particles or droplets must range between
1 μm and 5 μm in diameter (45, 46). In general, particles
larger than 5–6 μm are exhaled, while ultrafine particles
(1–2 μm) are usually deposited in the bronchioles.
Nanoscale particles (<1 μm) can be delivered to the alveoli.
Particles smaller than 20 nm, such as dendrimers are also
delivered to the alveoli, but they rapidly enter the
bloodstream and so become retained in the lungs (47).
In vitro, the endocytosis of nanoparticles is also
strongly dependent on their charge (48). As already
explained, PEGylation is a well-known process which
consists in attaching strands of polyethylene glycol to the
surface of certain molecules, thus changing the
conformation, electrostatic binding, hydrophobicity, and
immunogenicity of the molecule, resulting in enhanced
epithelial penetration, slower uptake, aggregation in and
degradation of nano-particulate formulations by the
reticuloendothelial
system,
longer
steady-state
concentrations, less frequent administrations, and lower
dosages. The first PEGylated drug approved by FDA in
1990 was ADAGEN, used to treat a form of severe
combined immunogenicity syndrome. PEGylation has
become a common characteristic of various medications
ever since (49).
PEGylation of nano-carriers could be beneficial, by
helping to overcome physiological barriers in the alveolar
epithelium, thus resulting in enhanced penetration across
the mucosal barrier and promoting entry into alveolar
epithelial cells (50). Another major impediment has been
overcome through the use of PEGylation, that is, the quick
uptake, aggregation in, and degradation of nano-particulate
formulations by the reticuloendothelial system. Through
PEGylating nano-carriers, the frequency of administration
and also the dosage can be reduced. Some studies have
proven a lower tendency to the aggregation of the

PEGylated nano-molecules, versus the non-PEGylated
ones. Aggregation can lead to the nanoparticle entrapment
in the liver, lungs, or elsewhere due to capillary occlusion
(51). So, various types of nanoparticles have been
developed over the last decades. These particles are able to
enhance the pharmacokinetics of multiple drugs,
potentially providing accurate and controlled drug delivery
(52).
The phrase “respiratory diseases” comprises multiple
disorders affecting the pulmonary system, the more
frequent ones being COPD, asthma, lung cancer, and
tuberculosis (53). The respiratory tract has several unique
advantageous anatomical and physiological features. The
large surface area, combined with an extremely thin lungblood barrier, provides direct access to the central
circulation while creating conditions that are well suited for
the efficient mass transfer, as shown by in vitro, ex vivo
and in vivo studies (54, 55).
Asthma is characterized by the chronic inflammatory
disorder of the airways associated with airway hyperresponsiveness, which leads to airway inflammation and in
time, to airway remodeling, with negative consequences on
the quality of life. The current treatment strategies include
inhaled corticosteroids, beta-agonist agents, and antileukotrienes. These treatments reduce the symptoms, but
do not prevent airway remodeling; moreover, long-term
use of corticosteroids may result in immunosuppression
and a predisposition to opportunistic infections. Various
particles have been evaluated for the treatment of asthma
that is refractory to classical therapies: liposomes, solidlipid NP, telodendrimers, polyethyleneimine, chitosan,
dendrimers, polylactic-co-glycolic acid, and CK30PEG
(polyethene glycol linked to a 30-mer of poly-L-lysine via
a single cysteine residue). CK30PEG is the latest new
molecule studied for nanoparticle’s gene delivery
therapeutic systems—not yet in use as it is still in phase I
clinical trials.
A recently completed clinical trial of inhaled gene
therapy has raised many questions about this type of
therapy (56). Validated studies indicate that steroids
compacted with nanoparticles are able to achieve
prolonged and higher benefits at the site of airway
inflammation, compared to free inhaled steroids. This is
probably a result of the prolonged and higher concentration
of drug in the targeted area, resulting in a sustained
bronchodilator effect (57). More recently, nano-particulate
formulations of interleukin antibodies have proven useful
in reducing asthma exacerbations in patients with allergic
asthma. Mepolizumab is an interleukin 5 antibody first
approved by the FDA in 2015 and showing promising
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results in reducing bronchial inflammation (58). Research
studies are now trying to incorporate this molecule into
nano-particulate formulations in order to enhance its
efficiency.
Chronic Obstructive Pulmonary Disease (COPD)
comprises emphysema and chronic bronchitis, which result
in a vast clinical presentation. Symptoms include difficulty
breathing, cough, sputum production, and wheezing.
Traditional treatments include anticholinergics, beta
agonists, and inhaled corticosteroids, which can control the
symptoms but do not cure the underlying disease. Many
designs have been reported so far in the attempt to find a
nano-therapeutic system that would be able to overcome
the challenges of drug delivery in COPD. The most recent
and promising model consists of an inhalable dry powder
containing dimethyl fumarate, designed by using advanced
particle engineering. The majority of the drug particles can
reach the lower airways through this new system, thus
providing an anti-inflammatory response in these
otherwise hard to reach areas, resulting in fewer
exacerbations, reduced symptoms such as dyspnea and
coughing. This treatment shows great promise, especially
in increasing the quality of life in COPD patients (52).
Lung cancer is one of the most common cancers in the
world, being the leading cause of cancer death worldwide.
Standard therapies currently include chemotherapy and/or
surgery. While chemotherapeutic agents effectively kill
cancer cells, their use and hence effectiveness are limited
by toxicity. The aim of the current research is to create a
multifunctional strategy delivered by a single molecule
which allows the detection, diagnosis, imaging, cell
destruction, and delivery of the drugs, decreasing drugrelated side effects. Polymeric micelle systems encoded
with a lung-cancer targeting peptide and encapsulated with
super magnetic iron oxide and Doxorubicin show great
promise in the field of target-specific treatment of lung
cancer. Nano-particulate formulations of classic
chemotherapeutic agents have proven useful in reducing
the chemotherapeutic side effects and increasing the 5-year
survival rate (53).
Tuberculosis is the leading cause of preventable deaths
worldwide. Nanoparticle-based drug delivery systems may
be considered for the treatment of tuberculosis due to the
slow and sustained release of drugs such as classic
tuberculostatic agents from the solid lipid nanoparticles
both in vitro and in vivo, thus meaning the patients will
undergo treatment fewer times per week, therefore
increasing adherence to treatment and also the quality of
life (50, 59, 60).
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One of the most debated topics regarding nanoparticulate formulations in the treatment of chronic
pulmonary diseases are the potential side effects of this
therapy. It is well-known that accidentally inhaled
nanoparticles such as Diesel smoke or air pollutants are
involved in the development of cardiovascular and
respiratory diseases, like pulmonary fibrosis and other
interstitial diseases. However, therapeutic nanoparticles
show different clearance patterns than the toxic ones. It has
been shown that non-biodegradable polymers provoke
more toxicity and inflammation than biodegradable
nanoparticles (54). A recent study reported that
hydrophobic materials were the only ones that induced an
inflammatory reaction, leading to asthma-like symptoms,
while hydrophilic materials did not induce acute
respiratory toxicity, which is why they are preferred as
often as possible (55).

Conclusions
This review summarizes the potential beneficial effects
of nanoparticle therapy in chronic lung diseases. Nanocarrier systems provide the advantage of sustained drug
release in lung tissue, resulting in reduced dosing
frequency and improved patient compliance. Further
studies focusing on understanding the mechanisms of
action of nanoparticles and improving their chemical
structure are required in order to better understand the
potential long-term risk of excipient toxicity and nanoscale
carriers.
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